obrixtamig
1438-0012
Phase 3 small_molecule active
Quick answer
obrixtamig for Small Cell Lung Cancer (SCLC) is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Small Cell Lung Cancer (SCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active